<i>In vivo</i> Treatment of a Severe Vascular Disease via a Bespoke CRISPR-Cas9 Base Editor

Christiano R. R. Alves(Harvard University), Patricia L. Musolino(Harvard University), Rachael K. Wood, Joana Ferreira da Silva(Harvard University), Leillani L. Ha(Massachusetts General Hospital), Nahye Kim(Harvard University), Hannah E. Stutzman(Massachusetts General Hospital), Vijai Krishnan(Massachusetts General Hospital), Mark E. Lindsay(Massachusetts General Hospital), Rachel A. Silverstein(Harvard University), Benjamin P. Kleinstiver(Harvard University), Lauren R. Fox(Massachusetts General Hospital), Casey A. Maguire(Harvard University), Pazhanichamy Kalailingam(National University of Singapore), Demitri de la Cruz(Harvard University), Luke H. Chao(Harvard University), Sabyasachi Das(Massachusetts General Hospital), Friederike M. C. Benning(Harvard University), Rajeev Malhotra(Brigham and Women's Hospital), Shengdar Q. Tsai(Harvard University), Rashmi Richa(Harvard University), Siobhán McCarthy(Massachusetts General Hospital), Takahiko Imai(Harvard University), Joseph Lawton(Harvard University), C.K. Fong(Massachusetts General Hospital), Shuqi Yun(Massachusetts General Hospital), Christian L. Lino Cardenas(Harvard University), Claire E. Shamber(Massachusetts General Hospital), David Y. Chung(Harvard University)
bioRxiv (Cold Spring Harbor Laboratory)
November 11, 2024
Cited by 3


Related Papers